Certainty China 2026

Date: Thursday, June 25, 2026

Time: 9:00am – 5:00pm

Location: Shanghai, China

Certainty by Certara provides valuable opportunities to connect you with industry leaders and modeling & simulation (M&S) experts. Certara’s experts and guest speakers present the latest regulatory updates, applied case studies, and the cutting-edge technologies including AI/ML related to Model-informed Drug Development, clinical pharmacology, Pharmacometrics, QSP, PBPK, and more.

We hope this annual event will help you connect with innovative researchers across various pharmaceutical companies and bring the innovations to your team.

Overview

Date & Time: 9:00am – 5:00pm, Thursday, June 25th
Reception desk opens at: 9:00am
Venue: Crowne Plaza Shanghai Jinxiu, 2nd floor
Registration fee: Free of charge

Register now

Agenda

Speakers’ biography (PDF): Coming soon
Timetable with speaker information (PDF): Coming soon

Morning Sessions

Global MIDD Regulatory Landscape: FDA & EMA Updates

Modeling & Simulation approaches used for regulatory submissions

QSP latest case studies across all development phases and regulatory

Strategy First: Translational modeling from preclinical to clinical - Case studies of FIH dose justification

Digital Data Flow (DDF) from 3D to 4D

Group photo & Lunch break & Demo booth

Afternoon Sessions

Enabling AI-driven Decision making from Discovery to Submissions Towards Increased Clinical Drug Candidate Success - Today and Future Vision

MIDD strategies to overcome clinical pharmacology challenges for regulatory approvals - Case studies of dose justification in late phase

[Guest Speaker] MIDD Boosts Innovative Drug Global Expansion: A Case Study of Sugemalimab's Approval by EMA & MHRA
Yucheng Sheng, PhD
Associate Vice President, Clinical Pharmacology, CStone Pharmaceuticals

[Guest Speaker] (TBC) The modeling of bispecific antibodies in dose selection

Qingqing Xiao, PhD
Principal scientist- Pharmacometrics, China Innovation Center of Roche

Optimal dosing, optimal outcomes: PBPK case studies for ADCs